PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Estradiol with medroxyprogesterone - Menopausal disorders

PAD Profile : Estradiol with medroxyprogesterone - Menopausal disorders

Keywords :
hormone replacement therapy, HRT, menopause, sequential combined therapy, continuous combined therapy, menopausal symptoms
Brand Names Include :
Tridestra, Indivina

Traffic Light Status

Status 1 of 2.

Status :
Non Formulary
Important
Formulations :
  • Tablets
Important Information :
Tridestra tablets - consider changing to a newer, 1st or 2nd line option.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
Non Formulary
Important
Formulations :
  • Tablets
Important Information :
Indivina tablets - consider changing to a newer, 1st or 2nd line option.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

No additional documents returned.

Committee Recommendations

Date
Committee Name
Narrative
03 July 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands APC has agreed a traffic light status and place in therapy for the treatments of menopausal disorders in line with the CKS recommenations:

Menopause | Health topics A to Z | CKS | NICE

Associated BNF Codes

06. Endocrine System
06.04.01. Female sex hormones and their modulators
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More